MADISON, WIS, September 28, 2016 – Cellular Dynamics International, Inc. (CDI), a FUJIFILM company and the leading developer and manufacturer of induced pluripotent stem cell (iPSC) products, today announced a new venture, named Opsis Therapeutics. Formed on July 31, Opsis Therapeutics is focused on discovering and developing novel medicines to treat patients suffering from retinal diseases. [Read more…]
Leveraging Access to New FUJIFILM Resources, Cellular Dynamics Considers Expansion
This week, I corresponded as a media expert on stem cells for Xconomy.com, a leading news channel focused on today’s high-tech economy.
The discussion point was how life has changed at Cellular Dynamics International (CDI) following the buy-out by FUJIFILM Holdings for $307 million in March 2015 and directions that CDI might take now that it has access to a new pool of resources.
The acquisition by FUJIFILM Holdings certainly brings with it advantages, including access to high-volume production and engineering technology, as well as strong financial reserves. The partnership also allows  CDI access to the patents and technologies held by a plethora of other companies owned by its new multinational parent company. [Read more…]
FUJIFILM Acquires Cellular Dynamics International (CDI)
TOKYO and MADISON, Wis., March 30, 2015 —Â FUJIFILM Holdings Corporation (President: Shigehiro Nakajima) (“Fujifilm”) and Cellular Dynamics International, Inc. (CEO: Robert Palay)Â (“CDI”), a leading developer and manufacturer of fully functioning human cells in industrial quantities, announced that the two companies have entered into a agreement whereby Fujifilm will acquire CDI via an all-cash tender offer to be followed by a second step merger. [Read more…]